title: Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection.
abstract: BACKGROUND
  Effective anti-Helicobacter pylori therapies with few side-effects are needed.
  
  
  OBJECTIVE
  To study the effectiveness of short-term triple therapy with amoxycillin, clarithromycin and either omeprazole or lansoprazole for eradication and healing of peptic ulcers.
  
  
  METHODS
  Patients with gastric or duodenal ulcers received amoxycillin (1 g b.d.), clarithromycin (500 mg b.d.) and lansoprazole (30 mg b.d.) (LAC) or omeprazole (20 mg b.d.) (OAC) for 7 days. Endoscopic examinations were performed before treatment and at least 4 weeks after completion of therapy. H. pylori status was confirmed by rapid urease test and histological examination (Giemsa stain) from gastric biopsies taken from both the antrum and the body.
  
  
  RESULTS
  A total of 356 patients were randomized in this single-blind study. On a per protocol basis, H. pylori was eradicated in 134 of 170 patients (79%) in the lansoprazole group and in 105 of 146 (72%) in the omeprazole group (P = 0.189); and in intention-to-treat analysis 72% and 62%, respectively (P = 0.043). Healing of the ulcers was obtained in 166 of 186 (98%), and in 139 of 146 patients (95%), respectively (P = 0.357). Side-effects occurred in two patients in the LAC group and in six in the OAC group B (four stopped therapy).
  
  
  CONCLUSIONS
  This study has shown that the two regimens are highly effective in healing duodenal ulcers and are well tolerated. Neither treatment achieves the ideal cure rate for H. pylori. Lansoprazole does not appear to have a significant advantage over omeprazole either in ulcer healing or in H. pylori eradication.
authors.affiliation: Department of Internal Medicine, Valduce Hospital, Como, Italy.
authors.forename: G C
authors.initials: GC
authors.lastname: Spinzi
authors.forename: L
authors.initials: L
authors.lastname: Bierti
authors.forename: A
authors.initials: A
authors.lastname: Bortoli
authors.forename: E
authors.initials: E
authors.lastname: Colombo
authors.forename: A M
authors.initials: AM
authors.lastname: Fertitta
authors.forename: G L
authors.initials: GL
authors.lastname: Lanzi
authors.forename: R
authors.initials: R
authors.lastname: Venturelli
authors.forename: G
authors.initials: G
authors.lastname: Minoli
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017291:Clarithromycin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010406:Penicillins / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D013276:Stomach Ulcer / Q000188:drug therapy / Q000473:pathology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D010406:Penicillins; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole